[Federal Register Volume 72, Number 247 (Thursday, December 27, 2007)]
[Notices]
[Page 73360]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-25045]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer Of Controlled Substances; Notice Of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 6, 2007, Noramco 
Inc., Division of Ortho, McNeil, Inc., 500 Swedes Landing Road, 
Wilmington, Delaware 19801, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053).....................  I
Morphine-N-oxide (9307)....................  I
Dihydromorphine (9145).....................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Opium, raw (9600)..........................  II
Opium extracts (9610)......................  II
Opium fluid extract (9620).................  II
Opium tincture (9630)......................  II
Opium, powdered (9639).....................  II
Opium, granulated (9640)...................  II
Poppy Staw (9650)..........................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Carfentanil (9743).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to bulk manufacture the above listed controlled 
substances for sale and distribution to manufacturers for product 
development and formulation.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administrator, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than February 25, 2008.

    Dated: December 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-25045 Filed 12-26-07; 8:45 am]
BILLING CODE 4410-09-P